Table 4 Age-standardized mean urinary concentrations (picomoles per mg creatinine) of estrogens and estrogen metabolites (EM) and multivariable-adjusted percent difference 1 across categories of green tea intake in postmenopausal women
From: Green tea intake is associated with urinary estrogen profiles in Japanese-American women
| Â | Categories of green tea intake | Â | ||||
|---|---|---|---|---|---|---|
|  | <1 per week (n = 62) | 1-6 times per week (n = 32) | 7+ times per week (n = 25) |  | ||
| Â | Urinary concentration | Urinary concentration | Percent difference | Urinary concentration | Percent difference | Ptrend |
Total Estrogens and Metabolites | 27.7 | 26.7 | −6.2% (-33.7%-32.6%) | 26.5 | −10.5% (-36.0%-25.1%) | 0.52 |
Parent Estrogens | 5.81 | 3.89 | −37.0% (-58.0%- - 5.4%) | 4.01 | −38.6% (-58.3%- - 9.6%) | 0.01 |
Estrone | 1.96 | 0.66 | −41.1% (-60.5%- - 12.0%) | 0.59 | −47.0% (-63.9%- - 22.3%) | 0.001 |
Estradiol | 2.06 | 1.36 | −41.5% (-65.9%-0.1%) | 1.46 | −36.0% (-61.8% -7.2%) | 0.09 |
2-Hydroxylation pathway | 6.41 | 4.13 | −33.6% (-57.2% -3.0%) | 5.92 | −15.1% (-44.4%-29.6%) | 0.48 |
2-Pathway catechols | 4.90 | 3.53 | −30.8% (-58.4%-15.1%) | 4.18 | −20.3% (-51.1%-30.0%) | 0.37 |
2-Hydroxyestrone | 4.12 | 2.42 | −31.5% (-59.0%-14.6%) | 3.29 | −24.9% (-54.3%-23.4%) | 0.27 |
2-Hydroxyestradiol | 0.65 | 0.4 | −15.3% (-58.4%-72.6%) | 0.80 | 6.7% (-45.1%-107.2%) | 0.83 |
2-Pathway methylated catechols | 1.18 | 0.89 | −26.9% (-50.6%-8.1%) | 1.39 | 9.7% (-24.8%-60.0%) | 0.54 |
2-Methoxyestrone | 0.72 | 0.48 | −35.8% (-61.3%-6.2%) | 0.68 | −6.2% (-42.7%-53.4%) | 0.85 |
2-Methoxyestradiol | 0.11 | 0.08 | −33.2% (-64.8%-27.0%) | 0.12 | 19.3% (-36.7%-124.8%) | 0.60 |
2-Hydroxyestrone-3-methyl ether | 0.2 | 0.25 | −19.4% (-52.8%-37.7%) | 0.45 | 34.9% (-19.1%-124.8%) | 0.17 |
4-Hydroxylation pathway EM | 1.01 | 0.67 | −40.1% (-59.2%- - 11.8%) | 1.04 | −13.6% (-40.6%-25.7%) | 0.60 |
4-Pathway catechol: 4-Hydroxyestrone | 0.81 | 0.49 | −39.1% (-61.7%- - 3.0%) | 0.73 | −18.0% (-47.6%-28.2%) | 0.43 |
4-Pathway methylated catechols | 0.16 | 0.13 | −14.1% (-49.0%-44.7%) | 0.25 | 48.8% (-10.4%-146.9%) | 0.11 |
4-Methoxyestrone | 0.12 | 0.09 | −9.5% (-45.7%-51.0%) | 0.15 | 69.1% (2.0%-180.4%) | 0.05 |
4-Methoxyestradiol | 0.02 | 0.02 | −29.9% (-70.7%-67.7%) | 0.07 | 87.2% (-19.3%-334.2%) | 0.08 |
16-Hydroxylation pathway | 12.9 | 15.9 | 19.5% (-24.8%-90.1%) | 13.4 | −1.6% (-37.4%-54.8%) | 0.95 |
16α-Hydroxyestrone | 1.15 | 1.22 | −6.7% (-42.1%-50.1%) | 1.25 | −22.1% (-50.6%-22.7%) | 0.27 |
Estriol | 5.41 | 7.24 | 24.3% (-32.4%-128.6%) | 5.85 | 3.5% (-42.8%-87.6%) | 0.91 |
16-Ketoestradiol | 4.28 | 5.09 | 20.5% (-22.1%-86.3%) | 3.86 | −18.5% (-46.8%-25.0%) | 0.36 |
16-Epiestriol | 0.88 | 0.77 | −20.6% (-48.9%-23.4%) | 0.91 | 6.4% (-30.5%-63.0%) | 0.75 |
17-Epiestriol | 0.15 | 0.11 | −8.8% (-53.5%-79.0%) | 0.16 | 1.6% (-46.2%-91.9%) | 0.94 |
Ratios | ||||||
Parent estrogens / estrogen metabolites | 0.27 | 0.17 | −37.8% (-57.2%- - 9.5%) | 0.18 | −32.6% (-53.3%- - 2.8%) | 0.04 |
2-Hydroxylation pathway / parent estrogens | 1.10 | 1.06 | 8.7% (-29.4%-67.4%) | 1.48 | 12.0% (-26.4%-70.6%) | 0.60 |
4-Hydroxylation pathway / parent estrogens | 0.17 | 0.17 | 6.0% (-37.4%-79.5%) | 0.26 | 32.5% (-21.2%-122.6%) | 0.28 |
16-Hydroxylation pathway / parent estrogens | 2.22 | 4.08 | 95.0% (25.5%-202.9%) | 3.34 | 57.1% (2.6%-140.5%) | 0.05 |
2-Hydroxylation pathway / 16-hydroxylation pathway | 0.50 | 0.26 | −50.2% (-70.6%- - 15.5%) | 0.44 | −19.9% (-51.7%-33.0%) | 0.41 |
4-Hydroxylation pathway / 16-hydroxylation pathway | 0.08 | 0.04 | −51.4% (-71.0%- - 18.6%) | 0.08 | −10.1% (-45.7%-48.8%) | 0.69 |
2-Hydroxylation pathway / 4-hydroxylation pathway | 6.34 | 6.15 | 7.6% (-14.9%-36.0%) | 5.70 | 2.6% (-18.9%-29.9%) | 0.87 |
4-Pathway methylated catechols / 4-pathway catechol | 0.20 | 0.26 | 37.3% (-23.3%-145.7%) | 0.35 | 86.1% (6.6%-225.0%) | 0.03 |
2-Pathway methylated catechols / 2-pathway catechols | 0.24 | 0.29 | 14.4% (-25.4%-75.4%) | 0.32 | 33.6% (-11.2%-100.8%) | 0.16 |